63.33
-1.31(-2.03%)
Currency In USD
Address
350 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America
Phone
650 624 3000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
498
First IPO Date
April 30, 2004
| Name | Title | Pay | Year Born |
| Robert I. Blum | CEO, President & Director | 1.51M | 1964 |
| James A. Spudich | Co-Founder & Member of Scientific Advisory Board | 21,938 | 1942 |
| Andrew Callos | Executive VP & Chief Commercial Officer | 845,965 | 1969 |
| Sung H. Lee | EVP & CFO | 893,932 | 1970 |
| Fady Ibraham Malik | Executive Vice President of Research & Development | 909,769 | 1964 |
| Isaac E. Ciechanover | EVP of Corporate Development & Chief Business Officer | 0 | 1971 |
| Jeff Lotz | Vice President of Sales & Operations | 0 | N/A |
| Jeffrey J. Hessekiel | Executive VP, Chief Legal & Administrative Officer | 0 | 1969 |
| John O. Faurescu | Senior Vice President, Deputy General Counsel & Corporate Secretary | 0 | N/A |
| Scott R. Jordan | Senior Vice President of Global Marketing & Commercial Strategy | 0 | N/A |
| Steven Cook | Senior Vice President of Global Supply Chain Operations & Technical Operations | 0 | 1959 |
| Holly Laughlin | VP of Accounting & Corporate Controller | 0 | N/A |
| Kari K. Loeser | VP & Chief Compliance Officer | 0 | N/A |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.